ArticleFrontiers in microbiology2018
The Rapid Emergence of Tigecycline Resistance in
Article in Frontiers in microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 95 citations in OpenAlex.
- Emergence and dissemination of extensively drug-resistant ST307Microbial genomics · 2026Article
- Phylogenetic diversification and fitness trade-offs of TetA variants in mediating eravacycline resistance inAntimicrobial agents and chemotherapy · 2026Article
- Molecular Epidemiology ofAntibiotics (Basel, Switzerland) · 2025Article
- Plasmid-associated clonal expansion drives department-preference transmission of carbapenem-resistantFrontiers in cellular and infection microbiology · 2025Article
- Clinical use of tigecycline may contribute to the widespread dissemination of carbapenem-resistant hypervirulentEmerging microbes & infections · 2024Article
- Mechanisms of tigecycline resistance in Gram-negative bacteria: A narrative review.Engineering microbiology · 2024Review
- Molecular mechanisms of tigecycline-resistance amongFrontiers in cellular and infection microbiology · 2024Review
- Multidrug-resistant ST11-KL64 hypervirulentFrontiers in pediatrics · 2024Article
- Comparative Genomic Analysis Reveals the Emergence of ST-231 and ST-395Microorganisms · 2023Article
- Predicting tigecycline susceptibility in multidrug-resistant Klebsiella species and Escherichia coli strains of environmental origin.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2023Article
- Serious Risk of Tigecycline Resistance in Escherichia coli Isolated from Swine Manure.Microbial ecology · 2023Article
- Intravenous Polymyxin B as Adjunctive Therapy to High-Dose Tigecycline for the Treatment of Nosocomial Pneumonia Due to Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2023Article
- Characterization of two multidrug-resistantFrontiers in microbiology · 2023Article
- Review
- Infection of Diabetes Foot Caused by Carbapenem-ResistantInfection and drug resistance · 2023Article
- Identification of NovelMicrobiology spectrum · 2022Article
- Problems Associated with Co-Infection by Multidrug-ResistantHealthcare (Basel, Switzerland) · 2022Review
- The Genetic Characteristics and Carbapenem Resistance Mechanism of ST307Antibiotics (Basel, Switzerland) · 2022Article
- Progressive Development of Cefiderocol Resistance in Escherichia coli During Therapy is Associated With an Increase in blaNDM-5 Copy Number and Gene Expression.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Article
- Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tigecycline is one of the last resort treatments for carbapenem-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.